
Oncology NEWS International
- Oncology NEWS International Vol 18 No 3
- Volume 18
- Issue 3
Oncolytics kicks off reovirus trial
Oncolytics will start a U.S. phase II trial on Reolysin (reovirus serotype 3) and chemotherapy for NSCLC. Oncolytics said that Reolysin, in combination with certain chemotherapeutics, results in more efficient and synergistic anti-cancer activity than when each agent is used on its own.
Oncolytics will start a U.S. phase II trial on Reolysin (reovirus serotype 3) and chemotherapy for NSCLC. Oncolytics said that Reolysin, in combination with certain chemotherapeutics, results in more efficient and synergistic anti-cancer activity than when each agent is used on its own.
Articles in this issue
over 17 years ago
Genetics opens new window on acute myeloid leukemiaover 17 years ago
Pralatrexate: Upfront Rx strategy for T-cell lymphomaover 17 years ago
Who's Newsover 17 years ago
Functional MRI boosts early staging of cervical cancerover 17 years ago
Unseen bone lesions flare up on post-Rx NSCLC scansover 17 years ago
Exercise jumpstarts quality of life in lung caover 17 years ago
Champions strikes deal with Concordiaover 17 years ago
PET/CT picks up additional lesions not found on chest CTover 17 years ago
Targeted therapies address hard-to-treat liver tumors






















































